Eric Padron

Eric Padron

Auto-generated profile, based on publicly available information

Eric Padron

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2022 in Leukemia
Verified
Journal Article
Open access
PDF file
Joseph KhouryJoseph Khoury
Joseph Khoury
ESEric Solary
Eric Solary
OAOussama Abla
Oussama Abla
YAYassmine Akkari
Yassmine Akkari
RARita Alaggio
Rita Alaggio
AHAndreas Hochhaus
Andreas Hochhaus
The upcoming 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours is part of an effort to hierarchically catalogue human cancers arising in various organ systems within a single relational database. This paper summarizes the new WHO classification scheme for myeloid and histiocytic/dendritic neoplasms and provides an overview of the principles and rationale underpinning changes from the prior edition. The definition and diagnosis of disease types continues to be based on multiple clinicopathologic parameters, but with refinement of diagnostic criteria and emphasis on therapeutically and/or prognostically actionable biomarkers. While a genetic basis for defining diseases is sought where possible, the classification strives to keep practical worldwide applicability in perspective. The result is an enhanced, contemporary, evidence-based classification of myeloid and histiocytic/dendritic neoplasms, rooted in molecular biology and an organizational structure that permits future scalability as new discoveries continue to inexorably inform future editions.

10 May 2021 in Journal of Clinical Oncology
Verified
Journal Article
Open access
DSDavid Sallman
David Sallman
ADAmy E. DeZern
Amy E. DeZern
GGGuillermo Garcia-Manero
Guillermo Garcia-Manero
DSDavid P. Steensma
David P. Steensma
GRGail J. Roboz
Gail J. Roboz
RKRami S. Komrokji
Rami S. Komrokji
PURPOSE: Approximately 20% of patients with TP53-mutant myelodysplastic syndromes (MDS) achieve complete remission (CR) with hypomethylating agents. Eprenetapopt (APR-246) is a novel, first-in-class, small molecule that restores wild-type p53 functions in TP53-mutant cells. METHODS: This was a phase Ib/II study to determine the safety, recommended phase II dose, and efficacy of eprenetapopt administered in combination with azacitidine in patients with TP53-mutant MDS or acute myeloid leukemia (AML) with 20%-30% marrow blasts (ClinicalTrials.gov identifier: NCT03072043 ). RESULTS: Fifty-five patients (40 MDS, 11 AML, and four MDS/myeloproliferative neoplasms) with at least one TP53 mutation were treated. The overall response rate was 71% with 44% achieving CR. Of patients with MDS, 73% (n = 29) responded with 50% (n = 20) achieving CR and 58% (23/40) a cytogenetic response. The overall response rate and CR rate for patients with AML was 64% (n = 7) and 36% (n = 4), respectively. Patients with only TP53 mutations by next-generation sequencing had higher rates of CR (69% v 25%; P = .006). Responding patients had significant reductions in TP53 variant allele frequency and p53 expression by immunohistochemistry, with 21 (38%) achieving complete molecular remission (variant allele frequency < 5%). Median overall survival was 10.8 months with significant improvement in responding versus nonresponding patients by landmark analysis (14.6 v 7.5 months; P = .0005). Overall, 19/55 (35%) patients underwent allogeneic hematopoietic stem-cell transplant, with a median overall survival of 14.7 months. Adverse events were similar to those reported for azacitidine or eprenetapopt monotherapy, with the most common grade ≥ 3 adverse events being febrile neutropenia (33%), leukopenia (29%), and neutropenia (29%). CONCLUSION: Combination treatment with eprenetapopt and azacitidine is well-tolerated yielding high rates of clinical response and molecular remissions in patients with TP53-mutant MDS and oligoblastic AML.

1 January 2017 in The Lancet Oncology
Verified
Journal Article
Closed access
NGNancy K Gillis
Nancy K Gillis
MBMarkus Ball
Markus Ball
QZQing Zhang
Qing Zhang
ZMZhenjun Ma
Zhenjun Ma
YZYuLong Zhao
YuLong Zhao
EPEric Padron
Eric Padron

30 October 2015 in Leukemia
Verified
Journal Article
Closed access
PDF file
DSD A Sallman
D A Sallman
RKR Komrokji
R Komrokji
CVC Vaupel
C Vaupel
TCT Cluzeau
T Cluzeau
SGS M Geyer
S M Geyer
EPE Padron
E Padron

20 November 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ANAziz Nazha
Aziz Nazha
RKRami Komrokji
Rami Komrokji
MMManja Meggendorfer
Manja Meggendorfer
XJXuefei Jia
Xuefei Jia
NRNathan Radakovich
Nathan Radakovich
MSMikkael A. Sekeres
Mikkael A. Sekeres
PURPOSE: Patients with myelodysplastic syndromes (MDS) have a survival that can range from months to decades. Prognostic systems that incorporate advanced analytics of clinical, pathologic, and molecular data have the potential to more accurately and dynamically predict survival in patients receiving various therapies. METHODS: A total of 1,471 MDS patients with comprehensively annotated clinical and molecular data were included in a training cohort and analyzed using machine learning techniques. A random survival algorithm was used to build a prognostic model, which was then validated in external cohorts. The accuracy of the proposed model, compared with other established models, was assessed using a concordance (c)index. RESULTS: The median age for the training cohort was 71 years. Commonly mutated genes included SF3B1, TET2, and ASXL1. The algorithm identified chromosomal karyotype, platelet, hemoglobin levels, bone marrow blast percentage, age, other clinical variables, seven discrete gene mutations, and mutation number as having prognostic impact on overall and leukemia-free survivals. The model was validated in an independent external cohort of 465 patients, a cohort of patients with MDS treated in a prospective clinical trial, a cohort of patients with paired samples at different time points during the disease course, and a cohort of patients who underwent hematopoietic stem-cell transplantation. CONCLUSION: A personalized prediction model on the basis of clinical and genomic data outperformed established prognostic models in MDS. The new model was dynamic, predicting survival and leukemia transformation probabilities at different time points that are unique for a given patient, and can upstage and downstage patients into more appropriate risk categories.

20 June 2013 in Blood
Verified
Journal Article
Open access
PDF file
EPEric Padron
Eric Padron
JPJeffrey S. Painter
Jeffrey S. Painter
SKSateesh Kunigal
Sateesh Kunigal
AMAdam W. Mailloux
Adam W. Mailloux
KMKathy McGraw
Kathy McGraw
PEPearlie K. Epling-Burnette
Pearlie K. Epling-Burnette
Key Points: GM-CSF–dependent STAT5 hypersensitivity is detected in 90% of CMML samples and is enhanced by signaling mutations. Treatment with a GM-CSF–neutralizing antibody and JAK2 inhibitors reveals therapeutic potential.